NCT06134531
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2023); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Incidence of treatment-emergent adverse events, and serious adverse events
Timeframe: 12 months
Dose Limited Toxicity (DLT) and Maximum Tolerated Dose (MTD)
Timeframe: 12 months
Secondary (12)
Peak Time (Tmax) of MR001
Maximum Plasma Concentration (Cmax) of MR001
Area under the Concentration versus Time Curve (AUC) of MR001
Elimination of Half-life (t1/2) of MR001
Clearance (CL) of MR001
Show 7 moreShow less
Volume of Distribution (Vd) of MR001
Objective Response Rate (ORR)
Progression Free Survival (PFS)
Overall Survival (OS)
Duration of Response (DOR)
Disease Control Rate (DCR)
Anti-drug Antibody (ADA)
Arms and interventions
MR001Experimental
The investigational product is MR001 which will be supplied in glass vials containing 50 mg of Freeze-dried powder. MR001 could be diluted in saline for intravenous (IV) administration.
Drugs: MR001
Sites
1 site in 1 country
- Nanfang Hospital, Southern Medical UniversityGuangzhou, Guangdong, China